U.S. Markets close in 1 hr 9 mins

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
187.15-1.02 (-0.54%)
As of 2:50PM EDT. Market open.
People also watch
BIIBGILDCELGMRKBMY
Full screen
Previous Close188.17
Open188.32
Bid187.14 x 300
Ask187.21 x 300
Day's Range186.87 - 188.96
52 Week Range133.64 - 191.10
Volume1,274,203
Avg. Volume2,796,482
Market Cap136.56B
Beta1.79
PE Ratio (TTM)17.05
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield4.60 (2.47%)
Ex-Dividend Date2017-08-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Pfizer Sues J&J, Accuses it of Preventing Inflectra Uptake
    Zacks4 hours ago

    Pfizer Sues J&J, Accuses it of Preventing Inflectra Uptake

    Pfizer (PFE) filed a lawsuit in a U.S. district court alleging that J&J is resorting to anticompetitive practices to prevent uptake of Inflectra.

  • See what the IHS Markit Score report has to say about Amgen Inc.
    Markityesterday

    See what the IHS Markit Score report has to say about Amgen Inc.

    Amgen Inc NASDAQ/NGS:AMGN

  • American City Business Journals2 days ago

    Amgen challenge to Genentech $6 billion cancer drug OK'd by FDA

    A "biosimilar" version of the cancer drug Avastin — Genentech Inc.'s best-selling oncology treatment — was approved Thursday by the Food and Drug Administration, potentially crimping the $6 billion franchise of the South San Francisco-based drug maker's Swiss parent. The drug, which Amgen Inc. (AMGN) and partner Allergan plc (AGN) will sell as Mvasi, also is known by the scientific name bevacizumab. The drug regulator's approval allows it to be used to treat metastatic colorectal cancer and types of lung, kidney, cervical and brain cancers.